{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:07:58Z","timestamp":1779944878699,"version":"3.53.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Autologous stem cell transplantation (ASCT) for the treatment of multiple myeloma and lymphoma patients has been reported to improve relapse-free (RFS) and overall survival (OS). Nonetheless, the impact on patient-reported outcomes, such as professional activity and health-related quality of life (HRQoL) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>In a cross-sectional two-center study, we collected data of 122 patients receiving high-dose chemotherapy followed by ASCT for multiple myeloma (MM) or lymphoma between 2007 and 2023 at two German tertiary care centers through standardized questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of all patients at diagnosis was 56 years (range 24\u201367 years). 17.9% of patients received a second ASCT. 55.0% and 61.9% of patients achieved a complete remission after first and second ASCT, respectively. The median time to resumption of employment was 167 days and the overall rate of return to work (RTW) was 56.0%. Following ASCT, 29.0% of patients reduced their working hours and 95.4% had a recognized disability status.<\/jats:p>\n                    <jats:p>The median quality of life\/health status QLQ-C30 score after ASCT was 66.7 out of 100. A QoL\/health status of &amp;lt; 50 was significantly associated with a lower rate of resumption of professional activity (HR 0.44, 95% CI: 0.26-0.78, p = 0.02). 86.0% of all patients reported fatigue symptoms. The QLQ-MY20 score for fears of the future was significantly higher than for disease symptoms and therapy side effects (p &amp;lt; 0.0001), indicating that after ASCT, psychological symptoms affected patients more than somatic aspects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study suggests that long-term toxicities of ASCT significantly impact patients\u2019 HRQoL and impair their professional activity. Treatment should include an assessment of mental health and socioeconomic status and provide necessary support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1779331","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:00:38Z","timestamp":1779944438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers"],"prefix":"10.3389","volume":"16","author":[{"given":"Anna Franziska","family":"Hamm","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Schleswig-Holstein","place":["Luebeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajelet","family":"Loesche","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Schleswig-Holstein","place":["Luebeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Eisfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital Muenster","place":["Muenster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenii","family":"Shumilov","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital Muenster","place":["Muenster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Leitner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Schleswig-Holstein","place":["Luebeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Letsch","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Schleswig-Holstein","place":["Kiel, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital Muenster","place":["Muenster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Schleswig-Holstein","place":["Luebeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Vanessa","family":"Wenge","sequence":"additional","affiliation":[{"name":"Department of Medicine A, University Hospital Muenster","place":["Muenster, Germany"]},{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School","place":["Boston, MA, United States"]},{"name":"Department Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Schleswig-Holstein","place":["Luebeck, Germany"]},{"name":"Department of Medicine A, University Hospital Muenster","place":["Muenster, Germany"]},{"name":"Department of Internal Medicine (Oncology and Hematology), University Medicine Oldenburg, Carl von Ossietzky University of Oldenburg","place":["Oldenburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-02278-5","volume-title":"The EBMT handbook: Hematopoietic stem cell transplantation and cellular therapies","author":"Carreras","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"23","author":"D\u2019Souza","year":"2017","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2016.0470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30105-8","article-title":"Daratumumab: a game changer in myeloma therapy","volume":"7","author":"Ludwig","year":"2020","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592487","article-title":"Multiple myeloma outpatient transplant program in the era of novel agents: state-of-the-art","volume":"10","author":"Martino","year":"2020","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0826-4","article-title":"The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T\u2019s come into focus","volume":"55","author":"Passweg","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","article-title":"The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"12","author":"Lu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.01.025","article-title":"Salvage high-dose chemotherapy for germ cell tumors","volume":"33","author":"Feldman","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous Transplantation for newly diagnosed multiple myeloma in the era of novel agent induction","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.501","article-title":"Patient-reported outcomes in clinical practice","volume":"2015","author":"Dobrozsi","year":"2015","journal-title":"Hematology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.021","article-title":"A comparative assessment of quality of life in patients with multiple myeloma undergoing autologous stem cell transplantation through an outpatient and inpatient model","volume":"24","author":"Martino","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704561","article-title":"A prospective study of health-related quality of life, fatigue, anxiety and depression 3\u20135 years after stem cell transplantation","volume":"34","author":"Hjermstad","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.304","article-title":"A prospective evaluation of patients\u2019 health-related quality of life during auto-SCT: a 3-year follow-up","volume":"46","author":"Fr\u00f6din","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1069\u2013e1080","DOI":"10.1200\/OP.21.00694","article-title":"Long-term health-related quality of life of autologous hematopoietic cell transplantation patients and nontransplant patients with aggressive lymphoma: a prospective cohort analysis","volume":"18","author":"Strouse","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280413","article-title":"Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life","volume":"107","author":"Smeland","year":"2022","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2198053","article-title":"Health-related quality of life, depressive symptoms, and chronic fatigue in long-term survivors of Hodgkin lymphoma","volume":"64","author":"Gulbrandsen","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"key":"B25","doi-asserted-by":"publisher","first-page":"649\u201355","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0035","article-title":"Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1125015","article-title":"Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation","volume":"55","author":"Kiserud","year":"2016","journal-title":"Acta Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S134603","article-title":"Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation","volume":"9","author":"Arboe","year":"2017","journal-title":"Clin Epidemiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01429-0","article-title":"Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma","volume":"56","author":"Granell","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/ejh.13298","article-title":"Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy","volume":"103","author":"Jackson","year":"2019","journal-title":"Eur J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf031","article-title":"Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation","volume":"13","author":"Hensel","year":"2002","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11764-009-0105-2","article-title":"Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation","volume":"4","author":"Kirchhoff","year":"2010","journal-title":"J Cancer Surviv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:00:39Z","timestamp":1779944439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1779331"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1779331","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1779331"}}